Four companies are likely to come up with updates around share buybacks this month. Wipro, Cyient, and Windlas Biotech will consider buyback proposals, while Aurobindo Pharma’s record date for its confirmed buyback is set for April 17. Aurobindo Pharma approved a buyback worth Rs 800 crore on April 6, with a buyback price fixed at Rs 1,475 per share, marking a premium of over 10% from the previous closing price of Rs 1,339.80 on NSE.
Wipro’s board will consider a buyback alongside its results for the January-March quarter of FY26 on April 16. This would be Wipro’s fifth buyback if approved. Cyient’s board will meet on April 23 to consider its first-ever share buyback proposal along with a final dividend for the financial year 2026.
Recent tax changes under the Finance Bill 2026 impose a 12% surcharge on capital gains from buybacks, applicable only to promoters, while non-promoter shareholders will be taxed under existing norms.
